Supplement Facts Panel: 21 CFR 101.36 Labeling Requirements

A Supplement Facts panel is the nutrition information panel on a US dietary supplement, presenting serving information and dietary-ingredient declarations under the Supplement Facts title.

Its operational role is consumer-facing communication. Keep it distinct from the records and decisions that support it:

• Complete product label: the panel is one component, not the entire package presentation. Reviewing it alone does not establish that the rest of the label is appropriate.
• Manufacturing formula: the panel describes declarations per serving, not ingredient charges or processing instructions. The master manufacturing record serves a different purpose.
• Analytical result: a laboratory measurement describes a tested sample under a particular method; it is supporting evidence, not a ready-to-print declaration.
• Batch disposition: an approved panel is not a decision to release a batch. That remains a human quality decision, distinct from artwork approval; see the quality control unit.

This article focuses on US dietary supplements. Other product categories and destination markets need a separate applicability assessment before this framework is used.

Binding provisions are identified through linked regulatory citations. The proposed workflows, data relationships and review checks are suggested operating designs—not regulatory templates, official guidance or statements of software capability. Use them to organize review without treating them as additional legal requirements.

Start with the product category and destination market, not an existing artwork template. The practical comparison below separates consumer-facing nutrition information from the manufacturing documents used to prepare and review it.

For US dietary supplements, 21 CFR 101.36(e)(1) specifies the Supplement Facts title. For US foods labeled under 21 CFR 101.9(d)(2), the identifying heading is Nutrition Facts. This distinction identifies the panel; title hierarchy and bolding belong in the format review.

The frameworks are not wholly disconnected. For US dietary supplements, 21 CFR 101.36(b)(2)(i)(B) requires the specified dietary ingredients to use nomenclature from section 101.9 or the alternative provision identified there. Follow the applicable cross-reference rather than importing an entire Nutrition Facts template.

For US dietary-supplement operations, 21 CFR 111.70(d) requires label specifications. That manufacturing-side duty is distinct from panel presentation. In practical document control, the specification defines the label being reviewed; artwork is its rendered presentation. See 21 CFR 111 manufacturing controls for the broader operational context.

As review practice, use the Master Manufacturing Record to understand the formula's manufacturing basis, not as ready-to-print consumer wording. For another destination, begin a separate applicability review—for example, UK supplement labelling—rather than treating US panel approval as transferable.

Establish the serving reference first

For US dietary supplements, 21 CFR 101.36(b)(1)(i) requires “Serving Size” beneath “Supplement Facts,” aligned on the left side of the panel. In practical reading order, this anchors the ingredient declarations to a stated serving before the reader encounters amounts. It is the reference point for interpreting the panel, not merely a heading positioned to fill available space.

For US dietary supplements under that provision, serving size must use terminology appropriate to the supplement’s form; the regulation gives tablets and capsules among its examples. For US dietary supplements, the same provision requires serving-size determination in accordance with §§ 101.9(b) and 101.12(b), Table 2. The serving basis therefore is not an arbitrary artwork choice; those cross-references govern its determination.

For US dietary supplements, 21 CFR 101.36(b)(1)(ii) requires “Servings Per Container” beneath “Serving Size,” also aligned on the left. Under that provision for US dietary supplements, this information need not appear there when it is stated in the net quantity of contents declaration. Keep that exception attached to the placement decision rather than treating a missing line as either automatically acceptable or automatically incorrect.

Choose ingredient placement from the actual declarations

For US dietary supplements, 21 CFR 101.36(b)(3)(i) permits other dietary ingredients in a column beneath the column of names described in paragraph (b)(2)(i)(B). This is a permitted arrangement, not the only display option.

For US dietary supplements under that provision, a linear display beneath the heavy bar described in paragraph (e)(6) is permitted as long as the constituents of an other dietary ingredient are not listed. The condition belongs with the layout option: available horizontal space alone does not establish whether that option applies.

For US dietary supplements under the same provision, if no paragraph (b)(2) dietary ingredients are declared, other dietary ingredients must appear directly beneath “Amount Per Serving.” This gives the layout a different starting point when that preceding ingredient group is absent.

Practical layout preparation

As an artwork-preparation practice, establish the ingredient grouping and whether constituents will be listed before choosing a template. For a proprietary blend, settle the intended declaration structure before allocating panel space. A useful layout brief records the serving terminology, the location of the container-count declaration, and the applicable ingredient-display branch. This keeps the designer’s task focused on implementing reviewed content rather than deciding its regulatory basis.

For US dietary supplements, 21 CFR 101.36(b)(3)(i) identifies other dietary ingredients as those without FDA-established RDIs or DRVs that are outside paragraph (b)(2), and requires their declaration by common or usual name when present.

As an ingredient-master review practice, use an identity crosswalk to separate purchasing terminology from the reviewed label declaration. A supplier’s commercial name is not, by itself, a completed labeling decision: it may identify a marketed material without resolving the ingredient’s declaration name or its role in the formula.

For botanical reviews, retain species, plant part and preparation description as applicable, linked to supporting botanical authentication information. These are suggested review-record fields, not a statement of mandatory panel wording. Keeping them separate helps reviewers assess whether similarly named supplier materials actually support the same proposed declaration.

For a proprietary blend, distinguish reviewer access to the detailed formula from the eventual printed declaration. A useful review record preserves constituent identities and their relationship to the blend rather than treating the blend name as a substitute for identity work. Check the current applicable labeling text for blend-specific disclosure and botanical naming questions before approving wording. Document unresolved naming questions for human review rather than silently copying supplier terminology into artwork.

Binding title-format rules

For US dietary supplements, 21 CFR 101.36(e)(1) requires the Supplement Facts title to be larger than all other print in the nutrition label. For US dietary supplements under that provision, the title must span the nutrition label’s full width unless impractical. The same provision requires the title and all headings on US dietary supplement nutrition labels to be bolded to distinguish them from other information.

These are typography-hierarchy rules, not a complete artwork specification. For minimum point sizes, box specifications and alternative layouts, check the current applicable text of 21 CFR 101.36 for the US dietary supplement package concerned rather than applying generic measurements.

Practical final-size proof checks

As print-production practice, review the exported production file at its intended printed size, not only the editable design file. A zoomed screen view can conceal size relationships and layout defects. Use the following checks to assess whether export and production preparation preserved the intended artwork:

• Compare the title with every other text element inside the panel; inspect actual type settings as well as visual prominence.
• Check for font substitution, lost bold styling and scaling that changes text size or panel proportions.
• Inspect line wrapping and clipped text, particularly near panel edges and in crowded headings.
• Check separators for shifts, overlaps or disappearance during export; compare their positions with the reviewed design.
• Where full-width title treatment is considered impractical, record the layout constraint for reviewer assessment rather than treating the qualification as a routine design option.

Keep the reviewed proof and observations together for the designated artwork reviewer or quality control unit. This is a practical review record, not a substitute for assessing the applicable format provisions.

For Supplement Facts preparation, a useful practice is to separate calculation inputs from approved artwork values. Use a worksheet with distinct fields rather than a single amount field that changes meaning during review.

Internal unit normalization makes compatible inputs easier to compare; it does not determine the eventual printed declaration. A controlled unit class library can provide a consistent vocabulary for this work. Retain the original quantity and unit alongside the normalized result, conversion factor and conversion rationale so another reviewer can reconstruct the conversion.

For Daily Value review, preserve the reference identifier and version, nutrient identity, intended label population and reviewer’s applicability decision. Keep that reference basis separate from both the ingredient quantity and the displayed percentage. This section does not prescribe numerical Daily Values or rounding rules.

Treat missing reference data as unresolved, not as zero or a value copied from another product. Flag the affected display decision for review. The worksheet supports reconstruction; the approved display value supports artwork preparation. Link subsequent changes to a documented recalculation review, preserving both functions.

A useful discrepancy review starts with an evidence comparison, not an acceptance percentage. The following is an industry-practice approach for supplement label review, not a regulatory tolerance rule.

• Identify the tested material and lot: raw ingredient, intermediate or finished product.
• Record the sample basis, analytical unit and reported result, including whether the result represents an individual unit or a composite sample.
• Identify the relevant panel declaration and applicable specification. Keep the label claim and release limit distinct rather than assuming they are interchangeable.
• Document the analytical method reference and any normalization, including inputs, conversion factors and the reason for each adjustment.

Common review scenarios expose mismatched comparisons. A raw-material assay is not itself a measurement of finished-product content. A per-capsule result needs a documented serving-basis conversion before comparison with a per-serving declaration. Results on a dry-weight basis and an as-is basis need a justified common basis; changing the unit label alone does not reconcile them.

Keep calculated expectations separate from measured results, and retain the original reported result alongside any normalized value. Review these relationships before deciding whether the discrepancy is real. Do not apply a general acceptance percentage, create an automatic pass rule or assume a formulation overage resolves a labeling discrepancy. For US dietary supplements, direct regulatory acceptance questions to the current applicable provisions of 21 CFR 101.36 and a product-specific assessment.

For an unresolved mismatch, open an exception record identifying affected label versions, supporting laboratory and manufacturing records, the reviewer and the decision or pending decision. Use the appropriate out-of-specification handling process where relevant; leave disposition to the responsible human review process.

For US dietary supplements, 21 CFR 111.70(d) requires manufacturers to establish label specifications. The workflow below is a suggested way to reconcile those specifications with manufacturing information; the cited provision does not independently prescribe these fields, record links or approval steps.

From formula to authorized artwork

1. Scope the product. Identify the product, intended market, dosage form and formula revision. Compare the formula reference with the relevant master manufacturing record, so the panel review starts from the composition intended for manufacture.
2. Review the serving basis. Record the serving description and the basis used to convert formula quantities into declarations. Resolve differences between manufacturing quantities and consumer-serving quantities before preparing the declaration set.
3. Prepare traceable declarations. Map each formula ingredient identifier to its declaration entry or document why no panel entry is proposed. Allow several ingredient records to support one declaration. Link each calculated declaration to its calculation record, inputs, units and basis.
4. Review artwork against the declaration set. Associate the reviewed entries with a specific artwork revision and proof. Compare the proof with that set rather than relying on resemblance to the previous label.
5. Resolve exceptions and authorize use. Record discrepancies, their disposition and any revised calculations or proofs. Route the reconciled version to designated human approvers under site procedures before making it available for use.

Ownership and the review snapshot

A practical division of responsibility gives formulation staff composition questions, the labeling reviewer declaration assessments, and artwork personnel implementation of reviewed content. Designated humans approve the result under site procedures; transferring a file between teams is not itself an approval.

Retain a review snapshot containing the formula revision, label specification revision, declaration basis, artwork revision, proof and reviewer decision together. This supports data integrity by design: a later reviewer can reconstruct what was assessed without substituting today’s formula or artwork. Identify the manufacturing-record revision within that snapshot so a subsequent composition change can be evaluated against the previously authorized panel.

The diagram below describes a proposed record structure. Its field names are neither a regulatory form nor a claim about any particular application.

Proposed data-model diagram

FormulaRevision → IngredientID ↔ DeclarationEntry ↔ CalculationRecord ReviewedDeclarationSet → ArtworkRevision → Proof ReviewSnapshot → FormulaRevision + ManufacturingRecordRevision + LabelSpecificationRevision + DeclarationBasis + ReviewedDeclarationSet + ArtworkRevision + Proof + ReviewerDecision

As a system-neutral practice, define handoffs by product identifier and source and receiving revision identifiers—not filenames alone. For every transfer, record the originating field, receiving field, unit or nonnumeric status, revisions and reviewer. This supports data integrity by design without prescribing a particular system.

• Formula record → calculation worksheet: component quantity → calculation input; retain quantity unit and batch basis; formulation reviewer.
• Ingredient master → calculation worksheet: material identity and strength → identity crosswalk and conversion input; retain strength unit and basis, marking names nonnumeric; ingredient-data reviewer.
• Calculation worksheet → artwork: reviewed ingredient name and serving amount → panel text and amount field; retain declaration unit and serving basis; labeling reviewer.
• Artwork → quality record: proof identifier and revision → approval-subject reference; mark units nonnumeric; quality reviewer.

Treat export or import success as a transport result, not content approval. Where manufacturing–quality record handoffs are involved, keep transfer status separate from the human review decision.

For recovery, identify affected records before correcting the originating issue. Regenerate dependent outputs, compare superseded and replacement revisions, and document a new human decision against the corrected proof. Retain the relationship between the exception and replacement records so reviewers can follow what changed.

Suggested recovery workflow: Identify affected records → Correct source → Regenerate outputs → Compare revisions → Human review and documented decision. These advisory steps do not authorize automatic quality release.

These hypothetical operational cases apply the serving, declaration and artwork checks covered above. They illustrate calculation dependencies and revision control, not regulatory serving-size determinations or acceptance criteria.

Case A: unchanged capsule, changed serving basis

• Input: The capsule formula is unchanged. Let q represent milligrams of a particular dietary ingredient per capsule and n represent capsules in the reviewed serving. The internal unrounded amount is q × n milligrams per serving.
• Reasoning path: If the reviewed serving basis changes, keep q fixed and recalculate using the revised n. Identify dependent amount-per-serving calculations and artwork fields, including the serving declaration, ingredient amounts and applicable Daily Value entries. Rebuild the comparison between the previous and proposed declarations. Selecting the serving basis and applying display rules remain separate review tasks.
• Exception decision: Do not treat the existing panel as suitable merely because the capsule formula is unchanged. Route the resulting declaration revision through change control for assessment before artwork approval.
• Retained record: Keep the prior and revised serving bases, calculation comparison, affected-field list and reviewer disposition together.

Case B: completed declaration review, obsolete artwork

• Input: Declaration review is complete, but an older artwork file enters print-proof review. The intended review snapshot identifies the reviewed declaration entries and their associated artwork revision.
• Reasoning path: Compare both the proof's revision and its declaration entries against that snapshot. Identify the mismatched fields rather than relying on the filename or visual similarity alone.
• Exception decision: Stop approval of the obsolete proof, replace it with the intended file through document control, and repeat the affected content and format checks. A reviewer then assesses the replacement proof.
• Retained record: Preserve the mismatch report, obsolete-file identifier, replacement revision, repeated proof-check results and final human approval decision.

Use this suggested practice checklist as a final review gate for a Supplement Facts panel, not as an exhaustive legal checklist or an assurance of compliance. Consult the relevant discussions above for interpretation; this gate checks whether the supporting decisions and records are ready for artwork approval.

Keep unresolved questions visible in the review record, with an owner, the affected proof revision and the information needed to close each issue. A cleaner-looking proof is not evidence that an underlying question has been resolved. Avoid undocumented edits that erase the reason for a change.

Use change control to connect corrections to their review decisions, and retain an audit trail of the sequence. Before closing the gate, identify the exact artwork revision reviewed and record the human decision against it. Where an issue remains open, record that status explicitly rather than treating silence or a file replacement as approval.